Symptoms and General Pathology

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Neoplasms

Gland and Hormone Related Diseases

Syndrome

Infertility

Infertility, Female

Polycystic Ovary Syndrome

Genital Diseases

Urogenital Diseases

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Reproductive Control Agents

Follicle Stimulating Hormone

Contraceptive Agents

Contraceptives, Oral

Contraceptives, Oral, Combined

Desogestrel

Hormones

Hormone Antagonists

Contraceptive Agents, Female

Contraceptives, Oral, Hormonal

Contraceptive Agents, Hormonal

Progestins

A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.

Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.

comparison between corifollitropin alfa and follitropin beta in IVM cycles

blood sampling

transvaginal ultrasound scanning

oocyte retrieval for IVM

Single injection of 100 micrograms of corifollitropin alfa

Corifollitropin Alfa

Daily injection (three days) of follitropin beta

Follitropin beta

Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.

oral contraceptive pill pretreatment (Marvelon)

The study will focus on important aspects related to follicle recruitment using exogenous gonadotropins in patients with polycystic ovaries:

1. Early follicle recruitment in patients with polycystic ovaries using corifollitropin alfa: does administration of this drug result in earlier and higher FSH (follicle stimulating hormone) concentrations above the threshold for follicle recruitment in an IVM (in vitro maturation) cycle preceded by oral contraceptive suppression, in comparison to normal daily administration of rFSH (recombinant follicle stimulating hormone, Puregon)?;
2. The maturation rate of the obtained oocyte-cumulus complexes in standard IVM media registered for clinical use: does stimulation with corifollitropin alfa versus recombinant FSH have an impact on the maturation rate and developmental capacity of the oocytes ?

Optimisation of Follicular Recruitment in IVM Cycles

A Comparison Between Corifollitropin Alfa and Recombinant FSH for Follicular Recruitment in Women With Polycystic Ovaries Who Undergo IVM Treatment

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Optimisation of Follicular Recruitment in IVM Cycles	NCT03197077	Infertility, Fe... Polycystic Ovar...	blood sampling transvaginal ul... oocyte retrieva... Corifollitropin... Follitropin bet... oral contracept...	18 Years - 36 Years	Universitair Ziekenhuis Brussel
Optimisation of Follicular Recruitment in IVM Cycles	NCT03197077	Infertility, Fe... Polycystic Ovar...	blood sampling transvaginal ul... oocyte retrieva... Corifollitropin... Follitropin bet... oral contracept...	18 Years - 36 Years	Universitair Ziekenhuis Brussel

Spots Global Cancer Trial Database for corifollitropin alfa